BioCardia's Total Assets for the quarter that ended in Dec. 2024 was $3.72 Mil.
During the past 12 months, BioCardia's average Total Assets Growth Rate was -28.20% per year.
During the past 3 years, the average Total Assets Growth Rate was -22.00% per year.
During the past 5 years, the average Total Assets Growth Rate was -7.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 44.70% per year.
During the past 13 years, BioCardia's highest 3-Year average Total Assets Growth Rate was 920.10%. The lowest was -85.40%. And the median was -5.10%.
Total Assets is connected with ROA %. BioCardia's annualizedROA % for the quarter that ended in Dec. 2024 was -183.85%. Total Assets is also linked to Revenue through Asset Turnover. BioCardia's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.
BioCardia Total Assets Historical Data
The historical data trend for BioCardia's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
BioCardia's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
BioCardia's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
BioCardia Total Assets Related Terms
Thank you for viewing the detailed overview of BioCardia's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BCDA has been successfully added to your 